Charles River launches rapid cell banking platform, cuts production timeline 40% vs industry standard
CRL•Rapid cell banking platform targets faster timelines
Charles River launched rapid cell banking programs targeting a 40% cut in cell bank production timelines versus the 20-week industry standard.
The offering combines rapid pre-bank and release testing with Next-Generation Sequencing-based characterization using the iDTECT platform to support regulatory submissions.
Rapid microbiological methods, including ATP-bioluminescence, replace compendial testing to speed microbial detection; real-time PCR shortens mycoplasma testing timelines.
CGMP-compliant NGS services aim to accelerate development while meeting FDA and EMA expectations, including ICH Q5A and Q5B guidance.
The Pathoquest acquisition strengthens in vitro sequencing capabilities for characterization and quality control testing of biopharmaceutical products.
